The chemical class referred to as C2CD6 inhibitors encompasses compounds that can indirectly affect the function of the C2 calcium-dependent domain-containing 6 protein by modulating calcium signaling pathways or related cellular processes. These compounds are not direct antagonists of the protein but can alter the cellular environment in a way that attenuates the activity of C2CD6. This modulation can occur through various mechanisms such as the blockade of voltage-dependent calcium channels by molecules like verapamil, diltiazem, nifedipine, and amlodipine, which prevents calcium ions from entering the cell and thereby influences processes that are dependent on calcium flux.
Further influence on calcium signaling comes from compounds like 2-APB, which modulates both IP3 receptors and store-operated calcium channels, and thapsigargin and ryanodine, which specifically disrupt calcium storage and release from the endoplasmic reticulum. Other chemicals, such as TMB-8, SKF-96365, and Xestospongin C, target intracellular calcium release and receptor-mediated calcium entry, which can alter signaling pathways within the cell. BAPTA-AM and cyclopiazonic acid contribute to this class by chelating intracellular calcium and inhibiting calcium pumps, respectively, further perturbing the calcium-dependent mechanisms that C2CD6 might be involved in.
SEE ALSO...
Items 11 to 12 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Cyclopiazonic Acid | 18172-33-3 | sc-201510 sc-201510A | 10 mg 50 mg | $173.00 $612.00 | 3 | |
Inhibitor of the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase, perturbing calcium homeostasis. | ||||||
Xestospongin C | 88903-69-9 | sc-201505 | 50 µg | $500.00 | 14 | |
Inhibits IP3 receptors, potentially altering intracellular calcium release. |